Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329728 | 1.00 | ADRB1 (0.64) | ADRB1GAAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL329640 | 1.00 | ADRB1 (0.64) | ADRB1GAAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31468714 | 1.00 | ADRB1 (0.64) | ADRB1GAAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21065736 | 0.98 | ADRB1 (0.62) | ADRB1GAAALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6767674 | 0.98 | ADRB1 (0.62) | ADRB1GAAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL329301 | 0.98 | ADRB1 (0.67) | ADRB1GAAALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16446848 | 0.95 | ADRB1 (0.64) | ADRB1GAAALDH1A1HPGDSMN1; SMN2 | |
| Bromide SCHEMBL7300370 | 0.95 | ADRB1 (0.64) | ADRB1GAAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21065768 | 0.95 | ADRB1 (0.64) | ADRB1GAAALDH1A1HPGDSMN1; SMN2 | |
| Lithium SCHEMBL31448665 | 0.95 | ADRB1 (0.64) | ADRB1GAAALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101177411-A | Method for synthesizing non-steroidal antiphlogiston tolmetin | UNIV TIANJIN TECHNOLOGY (CN) | 2008-05-14 | — | — | CN | claimed |
| CN-115215816-B | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024026424-A1 | QUINAZOLINONE DERIVATIVES AS AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-11738487-B2 | Processes for making molded flexible foams and flexible foams produced thereby | COVESTRO LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-115215816-A | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022218348-A1 | METHOD FOR SYNTHESIZING LACTAM COMPOUNDS | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2022-10-20 | — | — | WO | disclosed |
| CN-114805727-A | Process for preparing molded flexible foams and flexible foams prepared therefrom | 科思创有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20070054939-A1 | Thiazolypiperidine derivatives as mtp inhibitors | MERCK PATNET GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| CN-1256326-C | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | CN | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| EP-1636218-A1 | THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005003128-A1 | THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GMBH (DE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | ADRB1 2514/4885GAA 270/4885ALDH1A1 2963/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | ADRB1 124/4885GAA 3244/4885ALDH1A1 433/4885 |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SSTR2, SSTR5, SSTR3 | ADRB1 58/4885GAA 1299/4885ALDH1A1 812/4885 |
| US-20070054939-A1 | Thiazolypiperidine derivatives as mtp inhibitors | MTTP, CETP, APOB | ADRB1 364/4885GAA 872/4885ALDH1A1 955/4885 |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | ADRB1 1074/4885GAA 4572/4885ALDH1A1 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.